Chimanlall Goolcharran is a notable inventor based in Hopewell Junction, NY (US). He has made significant contributions to the field of biopharmaceuticals, particularly in the development of interleukin-1 (IL-1) antagonist formulations. With a total of 3 patents to his name, Goolcharran's work is pivotal in advancing therapeutic options for inflammatory diseases.

Latest Patents

Goolcharran's latest patents focus on stable liquid formulations of IL-1 antagonists. These formulations include a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. The IL-1 antagonist is preferably an IL-1 trap composed of a dimer of two fusion proteins with a specific amino acid sequence. His work also explores stable liquid formulations made with and without sodium chloride, as well as those made with phosphate or histidine buffer.

Career Highlights

Chimanlall Goolcharran is currently employed at Regeneron Pharmaceuticals, Inc., where he continues to innovate in the field of biopharmaceuticals. His expertise in formulating IL-1 antagonists has positioned him as a key player in the development of new therapeutic strategies.

Collaborations

Goolcharran collaborates with talented colleagues, including Daniel B Dix and Katherine Bowers. Their combined efforts contribute to the advancement of research and development in the biopharmaceutical sector.

Conclusion

Chimanlall Goolcharran's contributions to the field of interleukin-1 antagonist formulations highlight his innovative spirit and dedication to improving healthcare solutions. His work at Regeneron Pharmaceuticals, Inc. continues to pave the way for new treatments in inflammatory diseases.